Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 11/20 | 0.52 |
| ▸ | CES1 | P23141 | 10/20 | 0.52 |
| ▸ | MYC | P01106 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29972427 | 0.88 | CES2 (0.67) | CES2CES1RAB9A | |
| SCHEMBL3627482 | 0.84 | CES2 (0.61) | CES2CES1RAB9ANPC1HPGD | |
| Benzil SCHEMBL1515663 | 0.84 | CES2 (0.61) | CES2CES1RAB9ANPC1HPGD | |
| SCHEMBL28116434 | 0.83 | AKR1C3 (0.53) | MYCMAPK14POLB | |
| Benzil SCHEMBL10476771 | 0.83 | CES2 (0.54) | CES2CES1MYCRAB9AHPGD | |
| Benzil SCHEMBL10531234 | 0.83 | CES2 (0.54) | CES2CES1MYCRAB9AHPGD | |
| Benzil SCHEMBL10476773 | 0.83 | CES2 (0.54) | CES2CES1MYCRAB9AHPGD | |
| Benzil SCHEMBL10476776 | 0.83 | CES2 (0.54) | CES2CES1MYCRAB9AHPGD | |
| SCHEMBL166604 | 0.83 | CES2 (0.54) | CES2CES1MYCRAB9AHPGD | |
| SCHEMBL8801437 | 0.82 | CES2 (0.50) | CES2CES1RAB9ANPC1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1668015-B1 | CUCURBITURIL ASSEMBLY AND USES THEREOF | TECHNION RES & DEV FOUNDATION (IL) | 2013-08-21 | — | — | EP | disclosed |
| US-7875713-B2 | affinity pairs that can be efficiently utilized without being limited by factors such as chemical versatility, stability, irreversibility; for affinity chromatography, affinity labeling, immobilization, bioconjugation, immunohistochemical staining, flow cytometry, in situ hybridization, genetic mapping | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) | 2011-01-25 | — | — | US | disclosed |
| US-20060292570-A1 | Novel synthetic binding pairs and uses thereof | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) | 2006-12-28 | — | — | US | disclosed |
| EP-1668015-A2 | SYNTHETIC BINDING PAIRS COMPRISING CUCURBITURIL DERIVATIVES AND POLYAMMONIUM COMPOUNDS AND USES THEREOF | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION, LTD. (IL) | 2006-06-14 | — | — | EP | disclosed |
| WO-2005023816-A2 | SYNTHETIC BINDING PAIRS COMPRISING CUCURBITURIL DERIVATIVES AND POLYAMMONIUM COMPOUDS AND USES THEREOF | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) | 2005-03-17 | — | — | WO | disclosed |
| EP-0772601-A1 | 4,5-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1997-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060292570-A1 | Novel synthetic binding pairs and uses thereof | DBNL, GEMIN5, PICALM | CES2 1634/4885CES1 4527/4885MYC 968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.